Future healthcare for patients with the common pain disorder ‘fibromyalgia syndrome’ – fundamental changes based on the discovery of an immune cause

Recent laboratory advances have allowed re-conceptualising fibromyalgia syndrome, a common, severe chronic widespread pain condition, as an immune-mediated disease. This article summarises key findings and their implications for preventative strategies and future healthcare advances and their costs.